BR112015031027A2 - Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única - Google Patents
Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem únicaInfo
- Publication number
- BR112015031027A2 BR112015031027A2 BR112015031027A BR112015031027A BR112015031027A2 BR 112015031027 A2 BR112015031027 A2 BR 112015031027A2 BR 112015031027 A BR112015031027 A BR 112015031027A BR 112015031027 A BR112015031027 A BR 112015031027A BR 112015031027 A2 BR112015031027 A2 BR 112015031027A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- dosage form
- vitro method
- single dosage
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000007502 anemia Diseases 0.000 abstract 4
- 208000030507 AIDS Diseases 0.000 abstract 1
- 229940113151 HIF prolyl hydroxylase inhibitor Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- YOZBGTLTNGAVFU-UHFFFAOYSA-N roxadustat Chemical compound C1=C2C(C)=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C1OC1=CC=CC=C1 YOZBGTLTNGAVFU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361834808P | 2013-06-13 | 2013-06-13 | |
| US201361889478P | 2013-10-10 | 2013-10-10 | |
| US201361898885P | 2013-11-01 | 2013-11-01 | |
| US201361898890P | 2013-11-01 | 2013-11-01 | |
| US201361912185P | 2013-12-05 | 2013-12-05 | |
| PCT/US2014/040889 WO2014200773A2 (en) | 2013-06-13 | 2014-06-04 | Compositions and methods for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015031027A2 true BR112015031027A2 (pt) | 2017-08-29 |
Family
ID=52022903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015031027A BR112015031027A2 (pt) | 2013-06-13 | 2014-06-04 | Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única |
Country Status (37)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0713350B1 (pt) | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| JP6608355B2 (ja) | 2013-04-16 | 2019-11-20 | コーニンクレッカ フィリップス エヌ ヴェ | 表面ｅｃｇにおける両心室ペースメーカパルス検出のためのシステム及び方法 |
| NZ714963A (en) * | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| TWI846166B (zh) | 2013-11-15 | 2024-06-21 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ２−（５−（３−フルオロフェニル）−３−ヒドロキシピコリンアミド）酢酸の固体形態、その組成物及び使用 |
| UA123308C2 (uk) * | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| CN108401429A (zh) * | 2016-12-06 | 2018-08-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途 |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| AU2019265629B2 (en) | 2018-05-09 | 2024-09-12 | Akebia Therapeutics, Inc. | Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid |
| CA3159368A1 (en) | 2019-10-31 | 2021-05-06 | Akebia Therapeutics, Inc. | Therapeutic methods using vadadustat |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| WO2021222424A1 (en) * | 2020-04-29 | 2021-11-04 | BioAge Labs, Inc. | Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions |
| JP2023530452A (ja) | 2020-06-19 | 2023-07-18 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットの薬物間相互作用の調節 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| KR20230130035A (ko) | 2021-01-08 | 2023-09-11 | 아케비아 테라퓨틱스 인코포레이티드 | 바다두스타트를 사용하는 치료 방법 |
| JP2024510926A (ja) | 2021-03-01 | 2024-03-12 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットの薬物間相互作用の調節 |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| CA1261335A (en) | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
| CN1023479C (zh) | 1985-09-27 | 1994-01-12 | 弗·哈夫曼-拉罗切有限公司 | 乙二胺的单酰胺衍生物的制备方法 |
| TW219933B (enExample) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DK0650961T3 (da) | 1993-11-02 | 1997-09-15 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler. |
| ES2101420T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| WO1997041103A1 (de) | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CN1282319A (zh) | 1997-10-09 | 2001-01-31 | 小野药品工业株式会社 | 氨基丁酸衍生物 |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO1999048870A1 (en) | 1998-03-23 | 1999-09-30 | Aventis Pharmaceuticals Products Inc. | Piperididinyl and n-amidinopiperidinyl derivatives |
| GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| NZ508762A (en) | 1998-06-11 | 2003-07-25 | Upjohn Co | Delavirdine tablet formulation |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US7964216B2 (en) * | 2001-01-12 | 2011-06-21 | Sun Pharma Advanced Research Company Limited | Spaced drug delivery system |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US20040146964A1 (en) | 2001-03-21 | 2004-07-29 | Maxwell Patrick Henry | Assays, methods and means |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ES2414706T3 (es) * | 2001-12-06 | 2013-07-22 | Fibrogen, Inc. | Métodos para aumentar la eritropoyetina endógena |
| NZ536908A (en) | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
| WO2003101431A1 (en) * | 2002-06-04 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
| CN1678320A (zh) | 2002-08-29 | 2005-10-05 | 麦克公司 | N－联芳基甲基氨基环烷酰胺衍生物 |
| MXPA05004033A (es) | 2002-10-16 | 2005-06-08 | Isis Innovation | Hidroxilasas de asparaginil y moduladores de las mismas. |
| CA2506799A1 (en) | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| ATE443775T1 (de) | 2004-05-28 | 2009-10-15 | Fibrogen Inc | Hif-prolylhydroxylase-aktivitätstest |
| JP2008500951A (ja) | 2004-05-31 | 2008-01-17 | 田辺三菱製薬株式会社 | 二環化合物 |
| JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎を治療するための方法 |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| WO2006084210A2 (en) | 2005-02-04 | 2006-08-10 | Regents Of The University Of California, San Diego | Hif modulating compounds and methods of use thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| EP1893186A2 (en) | 2005-06-06 | 2008-03-05 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
| DE602006014843D1 (de) | 2005-06-15 | 2010-07-22 | Fibrogen Inc | Verwendung von hif 1alfa modulatoren zur behandlung von krebs |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| KR101313395B1 (ko) | 2005-09-12 | 2013-10-02 | 액테리온 파마슈티칼 리미티드 | 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물 |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| US7728130B2 (en) | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
| BRPI0706377A2 (pt) | 2006-01-09 | 2011-03-22 | Btg Int Ltd | moduladores de fator -1 induzìvel por hipoxia e usos relacionados |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| US20090176825A1 (en) | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| KR100798730B1 (ko) * | 2006-06-12 | 2008-01-29 | 신풍제약주식회사 | 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법 |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| BRPI0713350B1 (pt) | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| IES20070122A2 (en) | 2006-12-05 | 2008-05-28 | Michael Hilary Burke | A process for the preparation of an orally administered unit dose tablet |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| ES2377239T3 (es) | 2007-04-17 | 2012-03-23 | Ratiopharm Gmbh | Composiciones farmacéuticas que comprenden irbesartán |
| WO2008130508A1 (en) | 2007-04-18 | 2008-10-30 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| CA2683758A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| WO2008137060A1 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| US8309544B2 (en) | 2007-05-16 | 2012-11-13 | Merck Sharp & Dohme Corp. | Spiroindalones |
| KR20100016617A (ko) | 2007-05-18 | 2010-02-12 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 과증식성 장애 및 혈관형성 관련 질환의 치료에 유용한 저산소증 유도성 인자 （ｈｉｆ）의 억제제 |
| EP2186528B1 (en) | 2007-08-06 | 2014-03-19 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| CA2696725A1 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| US20100305154A1 (en) | 2007-11-30 | 2010-12-02 | Glaxosmithkline Llc | Prolyl Hydroxylase Inhibitors |
| EP2227770A4 (en) | 2007-11-30 | 2011-11-09 | Glaxosmithkline Llc | PROLYLHYDROXYLASEINHIBITOREN |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20110003013A1 (en) | 2008-01-04 | 2011-01-06 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| WO2009089547A1 (en) | 2008-01-11 | 2009-07-16 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| KR101208778B1 (ko) | 2008-03-03 | 2012-12-05 | 노파르티스 아게 | Ｔｌｒ 활성 조정제로서의 화합물 및 조성물 |
| ES2383273T3 (es) | 2008-07-23 | 2012-06-19 | F. Hoffmann-La Roche Ag | Compuestos heterocíclicos antivíricos |
| TW201006473A (en) * | 2008-08-13 | 2010-02-16 | Orient Pharma Co Ltd | Bi-layer medicine tablet containing Zaleplon |
| BRPI0913485A2 (pt) | 2008-09-15 | 2016-06-07 | Kasina Laila Innova Pharmaceuticals Private Ltd | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. |
| HU230877B1 (hu) * | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
| CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| US8137666B2 (en) * | 2008-11-22 | 2012-03-20 | Academia Sinica | Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses |
| EP2413930A4 (en) | 2009-03-31 | 2012-09-26 | Ligand Pharm Inc | ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY |
| SI2415771T1 (sl) | 2009-03-31 | 2013-12-31 | Kissei Pharmaceutical Co., Ltd. | Derivat indolizina in njegova uporaba v medicinske namene |
| TWI485150B (zh) | 2009-07-17 | 2015-05-21 | Japan Tobacco Inc | 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用 |
| ES2644998T3 (es) | 2009-11-06 | 2017-12-01 | Aerpio Therapeutics Inc. | Métodos para aumentar la estabilización del factor-1 alfa inducible por hipoxia |
| CN103429239A (zh) | 2011-01-13 | 2013-12-04 | 菲布罗根有限公司 | 增加网织红细胞血红蛋白含量的方法 |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| WO2012170442A1 (en) | 2011-06-06 | 2012-12-13 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| WO2013013609A1 (en) | 2011-07-22 | 2013-01-31 | Zhejiang Beta Pharma Incorporation | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| NZ714963A (en) * | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| US20160199434A1 (en) | 2013-08-16 | 2016-07-14 | Ohio State Innovation Foundation | Compositions and methods for modulating dna methylation |
| TWI846166B (zh) | 2013-11-15 | 2024-06-21 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| US20160339005A1 (en) | 2014-01-23 | 2016-11-24 | Akebia Therapeutics, Inc. | Compositions and methods for treating ocular diseases |
| JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ２−（５−（３−フルオロフェニル）−３−ヒドロキシピコリンアミド）酢酸の固体形態、その組成物及び使用 |
| EP3270922A4 (en) | 2015-03-20 | 2018-08-01 | Akebia Therapeutics Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| CN113382729A (zh) | 2018-10-03 | 2021-09-10 | 阿克比治疗有限公司 | 用于治疗炎症性障碍的苯并咪唑衍生物 |
| US11524939B2 (en) * | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
-
2014
- 2014-06-04 NZ NZ714963A patent/NZ714963A/en unknown
- 2014-06-04 MX MX2015017229A patent/MX378150B/es unknown
- 2014-06-04 PE PE2020000452A patent/PE20201496A1/es unknown
- 2014-06-04 SM SM20240092T patent/SMT202400092T1/it unknown
- 2014-06-04 KR KR1020247012967A patent/KR20240055172A/ko active Pending
- 2014-06-04 KR KR1020167000558A patent/KR102373245B1/ko active Active
- 2014-06-04 KR KR1020227037446A patent/KR102660040B1/ko active Active
- 2014-06-04 PL PL14811317.8T patent/PL3007695T3/pl unknown
- 2014-06-04 RS RS20240271A patent/RS65341B1/sr unknown
- 2014-06-04 DK DK14811317.8T patent/DK3007695T3/da active
- 2014-06-04 RU RU2016100363A patent/RU2705206C2/ru active
- 2014-06-04 NZ NZ753904A patent/NZ753904A/en unknown
- 2014-06-04 AU AU2014278543A patent/AU2014278543B2/en active Active
- 2014-06-04 MY MYPI2019003537A patent/MY204336A/en unknown
- 2014-06-04 PE PE2015002603A patent/PE20160194A1/es unknown
- 2014-06-04 WO PCT/US2014/040889 patent/WO2014200773A2/en not_active Ceased
- 2014-06-04 CN CN202111479746.1A patent/CN114404414A/zh active Pending
- 2014-06-04 CN CN202111479723.0A patent/CN114404413A/zh active Pending
- 2014-06-04 SG SG10201910773VA patent/SG10201910773VA/en unknown
- 2014-06-04 LT LTEPPCT/US2014/040889T patent/LT3007695T/lt unknown
- 2014-06-04 RU RU2019134558A patent/RU2019134558A/ru unknown
- 2014-06-04 FI FIEP14811317.8T patent/FI3007695T3/fi active
- 2014-06-04 ES ES14811317T patent/ES2974273T3/es active Active
- 2014-06-04 HU HUE14811317A patent/HUE066123T2/hu unknown
- 2014-06-04 HR HRP20240319TT patent/HRP20240319T1/hr unknown
- 2014-06-04 NZ NZ753905A patent/NZ753905A/en unknown
- 2014-06-04 EP EP24156067.1A patent/EP4360706A3/en active Pending
- 2014-06-04 CA CA2914662A patent/CA2914662C/en active Active
- 2014-06-04 SI SI201432066T patent/SI3007695T1/sl unknown
- 2014-06-04 MX MX2020006963A patent/MX391198B/es unknown
- 2014-06-04 KR KR1020217011294A patent/KR102461176B1/ko active Active
- 2014-06-04 SG SG11201509998WA patent/SG11201509998WA/en unknown
- 2014-06-04 US US14/897,849 patent/US11857543B2/en active Active
- 2014-06-04 JP JP2016519543A patent/JP2016521747A/ja active Pending
- 2014-06-04 CA CA3151685A patent/CA3151685A1/en active Pending
- 2014-06-04 PT PT148113178T patent/PT3007695T/pt unknown
- 2014-06-04 CN CN201480045048.2A patent/CN105451739A/zh active Pending
- 2014-06-04 BR BR112015031027A patent/BR112015031027A2/pt not_active Application Discontinuation
- 2014-06-04 EP EP14811317.8A patent/EP3007695B1/en active Active
- 2014-06-13 TW TW109141639A patent/TWI791177B/zh active
- 2014-06-13 TW TW111149765A patent/TWI856464B/zh active
- 2014-06-13 TW TW107141589A patent/TWI712411B/zh active
- 2014-06-13 TW TW113131294A patent/TW202446394A/zh unknown
- 2014-06-13 TW TW103120661A patent/TWI650126B/zh active
-
2015
- 2015-12-07 PH PH12015502738A patent/PH12015502738B1/en unknown
- 2015-12-08 DO DO2015000297A patent/DOP2015000297A/es unknown
- 2015-12-10 ZA ZA2015/09024A patent/ZA201509024B/en unknown
- 2015-12-10 IL IL24304715A patent/IL243047B/en active IP Right Grant
- 2015-12-11 CL CL2015003602A patent/CL2015003602A1/es unknown
- 2015-12-11 MX MX2022003510A patent/MX2022003510A/es unknown
-
2018
- 2018-08-17 CL CL2018002372A patent/CL2018002372A1/es unknown
-
2019
- 2019-05-14 JP JP2019091113A patent/JP6612479B2/ja active Active
- 2019-10-30 JP JP2019197138A patent/JP6937812B2/ja active Active
- 2019-10-31 IL IL270335A patent/IL270335B/en active IP Right Grant
-
2020
- 2020-02-07 AU AU2020200903A patent/AU2020200903B2/en active Active
- 2020-09-17 EC ECSENADI202058592A patent/ECSP20058592A/es unknown
- 2020-10-15 PH PH12020551705A patent/PH12020551705A1/en unknown
-
2021
- 2021-02-23 IL IL281058A patent/IL281058B2/en unknown
- 2021-08-31 JP JP2021140772A patent/JP7328291B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200570A patent/AU2022200570B2/en active Active
-
2023
- 2023-08-03 JP JP2023127201A patent/JP7672455B2/ja active Active
- 2023-11-16 US US18/511,042 patent/US20240335434A1/en active Pending
-
2024
- 2024-03-08 CY CY20241100181T patent/CY1126699T1/el unknown
- 2024-05-29 NO NO2024025C patent/NO2024025I1/no unknown
- 2024-06-03 NL NL301278C patent/NL301278I2/nl unknown
- 2024-06-04 CY CY2024016C patent/CY2024016I1/el unknown
- 2024-06-07 FR FR24C1025C patent/FR24C1025I2/fr active Active
- 2024-06-25 FI FIC20240023C patent/FIC20240023I1/fi unknown
- 2024-06-26 LT LTPA2024521C patent/LTPA2024521I1/lt unknown
- 2024-07-02 HU HUS2400023C patent/HUS2400023I1/hu unknown
- 2024-07-30 AU AU2024205219A patent/AU2024205219A1/en active Pending
-
2025
- 2025-04-22 JP JP2025070412A patent/JP2025114609A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015031027A2 (pt) | Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única | |
| ZA202006107B (en) | Compositions and methods for treating anemia | |
| WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
| BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
| NZ716765A (en) | Pharmaceutical combinations for the treatment of cancer | |
| BR112016026774A8 (pt) | uso de inibidores de proteassoma contendo boro após terapia de câncer primária e composição farmacêutica. | |
| UY34154A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel. | |
| CR20150660A (es) | Composiciones y metodos para tratar anemia | |
| AR104157A1 (es) | Composiciones y métodos para el tratamiento de la anemia | |
| CY1118071T1 (el) | Μεθοδος για τη διαλογη ενωσεων για τη θεραπεια καρκινου δια της αναστολης της αλληλεπιδρασης myd88/erk map κινασης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |